Giovanni is the most famous crime boss in Pokémon, but he isn't the only boss of Team Rocket. Someone else took over, and ...

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on VRDN stock, giving a Buy rating today.Pick the best stocks and maxi ...

WALTHAM, Mass., May 06, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for ...

The world will need about 3.7 million tons of copper beyond existing supply to meet 2030 demand, driven by the critical metal’s malleability, conductivity, corrosion resistance and antimicrobial ...

Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

About Viridian Metals. Viridian Metals is a leader in generative metal exploration with a focus on environmental responsibility and ethical practices.

Viridian Capital's latest report shows cannabis stocks pricing in no rescheduling or 280E relief, ... and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10.

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

Arlington’s Lake Viridian beach closure follows safety concerns after police cleared large crowds and residents expressed worries about public safety.

Viridian Southside Quarter. Bateh Perry Real Estate Investors & Loci Capital. By James Cannon – Editor in Chief, Jacksonville Business Journal. May 7, 2025. Updated May 7, 2025 3:30am EDT.

Viridian's thyroid eye disease drug veligrotug clears its first phase 3 trial, with data suggesting it could be competitive with Amgen's Tepezza.

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...